Free webinar on de-escalation of breast cancer treatments organised by EORTC and BIG


Breast cancer affects 1 in 8 women. It is the most common cancer in women worldwide, with nearly 2 million patients being diagnosed with the disease in 2018. Men get breast cancer too, though much less frequently.

The purpose of this webinar, which will take place during Breast Cancer Awareness month (October 2020), is to raise awareness about breast cancer and the importance of international academic research. The speakers are breast cancer experts and representatives from cancer research and patient organisations.

The main topic of this session will focus on the growing importance of treatment de-escalation to improve breast cancer patients’ quality of life by avoiding unnecessary over-treatment. Breast cancer experts from the EORTC and BIG networks will give examples of de-escalation clinical trials and will explain how they may help breast cancer patients by safely reducing treatment burden. A patient advocate will also give her perspective on this topic.

This session will be presented in English. The webinar is free and registration is mandatory. 

When and where: Wednesday 14 October 2020 from 1:00 to 2:00 p.m. CEST

Detailed programme

13:00-13:05  Brief introduction on global breast cancer research and de-escalation of breast cancer treatments – Prof. Etienne Brain, EORTC Breast Cancer Group Chair & BIG Executive Board member

13:05-13:10  Brief presentation of DESCRESCENDO study and introduction of the speakers – Prof. David Cameron, BIG Chair and EORTC Breast Cancer Group member

13:10-13:25  Tailoring radiotherapy after surgery to an individual patient’s risk of recurrence (EXPERT study – BIG Radio Tuning). Tailoring radiation dose escalation after surgery: cosmetic results and patient reported outcomes informing treatment decision-making (DCIS study) – Prof. Boon Chua, BIG Executive Board member & Study Principal Investigator of EXPERT and DCIS 

13:25-13:35  Using the biological characteristics of a tumour and novel diagnostic tests to help safely exclude chemotherapy (MINDACT study) – Prof. Fatima Cardoso, EORTC Breast Cancer Group and BIG member & Study Principal Investigator of MINDACT

13:35-13:45  Getting the patient’s perspective: Importance of giving patients the right information about de-escalation risks – Mrs Elizabeth Bergsten Nordstrom, EUROPA DONNA Executive Board member

13:45-14:00  Q&A session

Register HERE

This session is organised by two international non-profit organisations based in Brussels:

The European Organisation for Research and Treatment of Cancer (EORTC) is an independent non-profit cancer research organisation. Its mission is to coordinate and conduct international translational and clinical research to improve the standard of cancer treatment for patients.

The Breast International Group (BIG) is an international non-profit organisation which represents the largest global network of academic research groups dedicated to finding better treatments and cures for breast cancer.